Key Highlights
- On April 7, Circle director Rajeev Date offloaded 1,273 CRCL shares at $95 apiece, netting $120,935 through a pre-established Rule 10b5-1 trading arrangement
- Date’s stake declined 0.83% to 152,328 shares, maintaining a position valued above $14.4 million
- The company exceeded Q4 earnings projections with $0.43 EPS versus $0.25 consensus, while revenue reached $770.23 million—a 76.9% annual increase
- Compass Point slashed CRCL to Sell with a $77 target, warning of gross margin deterioration expected in the first half of 2026
- Wall Street consensus remains at Hold with a mean target of $126.29; institutional heavyweights like Vanguard expanded holdings during Q3
Rajeev Date, a director at Circle Internet Group, executed a sale of 1,273 CRCL shares on April 7, 2026. The transaction occurred at an average selling price of $95.00 per share, generating proceeds of $120,935.
This divestment was carried out through a Rule 10b5-1 trading plan established beforehand, indicating the transaction was pre-scheduled rather than prompted by current market conditions. Date maintains ownership of 152,328 shares worth approximately $14.47 million.
The sale represented a modest 0.83% reduction in his overall position, suggesting limited impact on his total holdings in the company.
The insider transaction unfolds amid diverging analyst views on CRCL. On April 8, Compass Point downgraded the stock to Sell, lowering its price objective from $79 down to $77. This target suggests potential downside of roughly 18% from prevailing trading levels at that time.
Compass Point’s downgrade hinges on margin concerns. The firm anticipates gross margin compression during early 2026, attributing this to USDC supply migrating toward lower-margin segments. Circle’s gross profit margin over the trailing twelve months registered just 8.67%.
Analyst Flags Margin Erosion Risk
Compass Point’s 2027 EBITDA projection lands 20% beneath consensus Street estimates. The analyst firm attributed recent stock strength to market expectations for margin improvement—a scenario it now disputes.
Shares currently command approximately 40 times bullish 2027 EBITDA projections. Those estimates hinge on assumptions that USDC growth reaccelerates in Q2 2026, a premise Compass Point questions.
CRCL has declined 37% over the past half-year despite robust revenue expansion of nearly 64% during the same timeframe. Markets continue grappling with the disconnect between strong top-line performance and margin pressures.
However, bearish sentiment isn’t universal. Robert W. Baird elevated its price objective to $138 in March while maintaining an Outperform stance. Morgan Stanley holds an Equal Weight rating with an $80 target, citing regulatory uncertainties surrounding stablecoin legislation.
Wells Fargo reduced its target from $128 to $111 in February but retained an Overweight rating. Goldman Sachs boosted its target to $88 alongside a Neutral rating. The average Wall Street price target currently stands at $126.29, with consensus landing at Hold.
Major Institutions Expand Positions
Despite analyst reservations, institutional investors were actively accumulating shares through Q3. Vanguard boosted its stake 61.6%, currently controlling 5.58 million shares valued at approximately $739.6 million.
CloudAlpha Capital Management expanded its holdings by 181.1% to 283,964 shares. Rheos Capital Works increased its position 20.8%, bringing total ownership to 302,000 shares.
Circle’s latest quarterly performance, disclosed February 25, delivered EPS of $0.43 compared to the $0.25 consensus forecast. Revenue totaled $770.23 million, marking a 76.9% year-over-year surge.
On the product front, Circle introduced the Circle Payments Network Managed Payments service, a stablecoin settlement solution enabling banks to leverage USDC for transactions without direct digital asset management. Triple-A also joined the network to facilitate stablecoin-to-local currency conversions for cross-border payment flows.
CRCL’s 52-week trading range spans $49.90 to $298.99. The stock’s 50-day moving average sits at $87.06, while the 200-day average stands at $95.30.



